News2020-05-23T14:50:18+00:00

Read Our Recent News

NanoMab and Lantheus enter into License Agreement Regarding the Commercial Development of 99mTc-NM-01

Date: May 29th, 2019 NanoMab and Lantheus enter into License Agreement Regarding the Commercial Development of 99mTc-NM-01 Shanghai, China, May 29th, 2019. NanoMab announced a collaboration with Lantheus Medical Imaging, Inc. (LMI) to provide 99mTc-NM-01 as clinical research tool, together with support and analytics, to pharmaceutical companies and the largest academic centers conducting clinical research in immuno-oncology in North America and Europe. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in [...]

May 29th, 2019|

Gary Cook won 2nd Oral Prize of British Nuclear Medicine Society

Date: April 1st-3rd, 2019 Gary Cook won 2nd Oral Prize of British Nuclear Medicine Society London, UK, April 1st-3rd, 2019. Gary Cook, scientific advisor of NanoMab presented 99mTc-NM-01 clinical data at the annual meeting of British Nuclear Medicine Society (BNMS) and was awarded with 2nd Oral Prize for his presentation ‘Imaging Programmed Cell Death Ligand-1 (PDL1) Expression in Non-Small Cell Lung Cancer with 99mTc anti PDL1 sdAb SPECT’.   99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and [...]

April 1st, 2019|

NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine

Date: Feb 22nd, 2019 NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine Shanghai, China, February 22nd, 2019. NanoMab published its FIH data for the first 16 patients of 99mTc-NM-01 on Journal of Nuclear Medicine (JNM), titled ‘Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer’. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression [...]

February 22nd, 2019|

NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study

Date: Feb 7th, 2019 NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study London, UK, February 7th, 2019. NanoMab announced a collaboration with Guy’s and St Thomas’ NHS Foundation Trust on the investigator-initiated study for 99mTc-NM-01. The primary objective is to assess the change in PD-L1 expression in relation to immunotherapy in NSCLC and melanoma patients. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression [...]

February 7th, 2019|

NanoMab and King’s College London to Collaborate on Next Generation One Step Radiolabelling

Date: Sep 12th, 2018 NanoMab and King’s College London to Collaborate on Next Generation One Step Radiolabelling Shanghai, China, September 12th, 2018. NanoMab announced a collaboration with the School of Biomedical Engineering and Imaging Sciences, King’s College London for the development of next generation single step radiolabelling for 99mTc/188Re.

September 12th, 2018|

Contact Us With Any Questions

Please do not hesitate to get in touch with any questions.

CONTACT US